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CilostazolOsteoclasts are bone-speciﬁc multinucleated cells generated by differentiation of monocyte/macrophage hema-
topoietic lineages and degrade bone matrix by secretion of lytic enzymes. The regulation of osteoclast differenti-
ation provides a potential strategy for treatment of bone-lytic damage. In this study, cilostazol, an inhibitor of
type III phosphodiesterase, inhibitedRANKL [receptor activator of nuclear factor kappa B (RANK) ligand]-induced
RANK expression in bone marrow-derived monocyte/macrophage precursors (BMMs) and Raw 264.7 cells by
inhibiting PU.1 via SIRT1 activation. RANKL-induced RANK expression was attenuated by cilostazol and rSIRT1
in Raw264.7 cells, and thesewere blocked by sirtinol. In linewith these, cilostazol elevated SIRT1mRNA and pro-
tein levels in 12–24 h and increased SIRT1 activity, and these effects were inhibited by sirtinol. Furthermore, the
RANKL-induced nuclear expression of PU.1, a transcription factor required for macrophage differentiation, was
suppressed by cilostazol. Additionally, marked RANKL-induced RANK immunoﬂuorescence staining in Raw
264.7 cells was attenuated by cilostazol and rSIRT1, and both attenuations were prevented by sirtinol. Extensive
RANK staining of knee synovial tissues in a mouse model of collagen-induced arthritis (CIA) was markedly re-
duced by cilostazol (30 mg/kg/day). In line with these results, both RANKL- and M-CSF-induced differentiation
of BMMs tomultinucleated TRAP+ giant cells and resorption pit formationwere inhibited by cilostazol associated
with a decrease in TRAP (amarker enzymeof osteoclasts) activity. In conclusion, cilostazol activates SIRT1,which
suppresses the nuclear translocation of PU.1, and thus, inhibits RANKL-stimulated RANK expression and causes
anti-osteoclast formation in BMMs in vitro and in their murine model of CIA.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease charac-
terized by the presence of inﬂammatory synovitis accompanied by the
destruction of joint cartilage and bone [1]. Many studies have reported
that multi-nucleated giant cells with the phenotypic features of osteo-
clasts are present at erosion sites in RA and in animal models of
collagen-induced arthritis (CIA) [2,3].
Osteoclast precursor cells derived from hematopoietic cells undergo
differentiation to tartrate-resistant acid phosphatase (TRAP)-positive
mononuclear cells in the presence of macrophage colony stimulating
factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), and
then fuse to form multinucleated cells that resorb bone [4,5]. RANKL, a
member of the tumor necrosis factor family, is produced by osteoblasts
and bone marrow stromal cells [6,7], and plays a role in osteoclast dif-
ferentiation and activation [8]. RANK, a receptor for RANKL, is expressed
on the surfaces of preosteoclasts and plays an important role during os-
teoclastogenesis [9]. RANKL binds to RANK on osteoclast precursors and
induces osteoclast differentiation in the presence of M-CSF [10].Interestingly, Pettit et al. [11] found that RANKL-knockout mice were
protected from bone erosion in a serum transfer model of arthritis.
Therefore, it is plausible that control of the RANKL/RANK signaling
pathway provides a means of suppressing osteoclast differentiation/
activation.
On the other hand, multiple transcription factors, such as, PU.1, c-
Fos, and NF-κB have been reported to determine osteoclast fate [12].
Kwon et al. [13] reported that PU.1 (a hematopoietic transcription fac-
tor) is critical for osteoclastogenesis, and that the regulation of RANK
gene transcription by PU.1 is required for osteoclast differentiation.
Cilostazol, an inhibitor of type III phosphodiesterase [14], was ap-
proved for use in the treatment of intermittent claudication by the
Food and Drug Administration [15]. Thereafter, cilostazol has been fo-
cused in vasculoprotective/antiatherogenic efﬁcacy in peripheral arteri-
al disease patients. Intriguingly, we found that cilostazol suppressed
proliferation of synovial ﬁbroblasts from RA patients by enhancing
apoptosis with increased cytochrome c release and apoptosis-inducing
factor translocation as well as increased caspase 3 activation via media-
tion of cAMP-dependent protein kinase activation-coupled Nrf2-linked
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ther reported that cilostazol signiﬁcantly suppressed LPS-induced TLR4
expression by blocking PU.1 transcriptional activity in synovial macro-
phages obtained from RA patients. In addition, cilostazol suppressed
IκBα degradation, the nuclear translocation of NF-κB p65, associated
with reduced production of the cytokines TNF-α and IL-1β [17]. Fur-
thermore, synovial inﬂammation and bone erosion were signiﬁcantly
inhibited by cilostazol treatment in a murine CIA model. Recently, it
was found that cilostazol like resveratrol (a known SIRT1 activator) ele-
vatedHMGB1-induced decreased SIRT1 protein expression and activity,
whereas HMGB1-stimulated NF-κB activationwas strongly inhibited by
cilostazol [18]. Shakibaei et al. [19] reported that RANKL up-regulated
p300 (a histone acetyltransferase) expression,which, in turn, promoted
NF-κB acetylation. In addition, resveratrol inhibited RANKL-induced
acetylation and the nuclear translocation of NF-κB. In addition, the acti-
vation of SIRT1 (a histone deacetylase) by resveratrol induced SIRT1-
p300 association in bone-derived and preosteoblastic cells, which led
to the deacetylation of RANKL-induced NF-κB, inhibition of NF-κB tran-
scriptional activation, and osteoclastogenesis.
These previous reports led us to hypothesize that inhibition of PU.1-
linked RANKL/RANK signal pathways by cilostazol might provide an ef-
fective therapeutic strategy for the suppression of osteoclastogenesis. In
the present study, we investigated themolecularmechanisms bywhich
cilostazol inhibits osteoclast differentiation in a background of arthritis
by focusing on the effects of cilostazol on PU.1-associated RANK expres-
sion. We also speciﬁcally assessed the notion that cilostazol inhibits
RANKL-induced osteoclastogenesis by inhibiting the nuclear transloca-
tion of PU.1 via SIRT1 activation.
2. Materials and methods
2.1. Reagents and antibodies
Recombinant SIRT1 was obtained from Sigma (St. Louis, MO).
Sirtinol was from Calbiochem (San Diego, CA). Recombinant murine
M-CSF and recombinant murine sRANK Ligand were purchased from
Peprotech (Rocky Hill, NJ). PU.1, c-Fos, c-Jun and NFATc1 antibodies
were from Cell Signaling (Danvers, MA). NF-κB p65, SIRT1, RANK and
histone H1 antibodies were purchased from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA). Dentin slices were obtained from Immunodiag-
nostic System (Scottsdale, AZ). Cilostazol (OPC-13013) [6-[4-(1-
cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)-quinolinone]
was donated byOtsuka Pharmaceutical Co. Ltd. (Tokushima, Japan), and
was dissolved in dimethyl sulfoxide to produce a 10mM stock solution.
2.2. Animals
Male C57BL/6 mice (8 weeks of age) were obtained from Samtako
Inc. (Osan, Gyunggi-do, South Korea). All experiments involving ani-
mals conformed to theGuide for the Care andUse of Laboratory Animals
published by the US National Institutes of Health (NIH Publication No.
85-23, revised 2011). In addition, all experimental procedures were
conducted in accordance with the Animal Care Guidelines issued by
the Pusan National University Institutional Animal Care and Use
Committee.
2.3. Induction and monitoring of collagen-induced arthritis (CIA)
Male DBA/1J mice were purchased from Japan SLC, Inc. (Shizuoka,
Japan). Mice were used for experiments when 8–12 weeks old. To pro-
duce the CIA model, 100 μg of bovine type II collagen (Chondrex, Red-
mond, WA) dissolved in 0.1 M acetic acid was emulsiﬁed with an
equal volume of Freund's complete adjuvant (Sigma, St. Louis, MO).
Mice were sensitized by an intradermal injection at the tail base and a
booster dose (containing CII and Freund's incomplete adjuvant)was ad-
ministered in the same manner on day 21 after the initial injection.Cilostazol (30 mg/kg/day) was administered intraperitoneally begin-
ning on day 22. Mice were euthanized on day 38, and knee joints
were isolated.
2.4. Bone marrow-derived cell isolation and culture
Bone marrow cells were isolated from 8 week-old male of DBA/1J
mice. Brieﬂy, bone marrow cells harvested from femurs and tibiae
were washed and incubated in α-MEM containing 10% FBS and M-CSF
(5 ng/ml). After 24 h, non-adherent cells were harvested and layered
on a Ficoll-Hypaque gradient (Sigma) and cultured in α-MEM contain-
ing 10% FBS. After 1 h, culture dishes were washed to remove non-
adherent cells. Adherent osteoclast precursor cells were then incubated
with M-CSF (30 ng/ml) and RANKL (100 ng/ml). Raw 264.7 cells
(American Type Culture Collection) were cultured in DMEM containing
10% FBS.
2.5. Formation of osteoclastogenesis
Osteoclast precursor cells from BMMs ofmicewere cultured in a 96-
well tissue culture plate with dentin slices (IDS, Boldon, UK). Cultures
were maintained in α-MEM containing 10% FBS, M-CSF (30 ng/ml),
and RANKL (100 ng/ml) in the presence of cilostazol (30 μM) for
28 days. Half of the culture medium was replaced with fresh medium
every 3 days. Pit formation images were obtained using a HITACHI
S3500N scanning electron microscope (Hitachi High-Technologies).
2.6. Tartrate-resistant acid phosphatase (TRAP) staining and TRAP activity
TRAP staining was performed using an acid phosphatase, leukocyte
(TRAP) stain kit (Sigma). Images of TRAP-positive multinuclear cells
containing more than three nuclei were obtained by microscopy
(Axiovert 200, Carl Zeiss, Oberkochen, Germany). To determine TRAP
activity, adherent cells were ﬁxed with 10% formaldehyde for 10 min,
95% ethanol for 1 min, and air dried. Phosphate substrate solution
(100 μl) containing 3.7mMp-nitrophenyl phosphate and 100mM sodi-
um tartrate in 50 mM citrate buffer was then added to the ﬁxed cells.
After incubation for 10 min, the mixtures in wells were transferred to
new plates containing 100 μl of 0.1 N NaOH, and absorbance at
405 nmwasmeasured using an ELISA reader (Bio-Tek instruments,Wi-
nooski, VT).
2.7. SIRT1 deacetylation assay
In vitro deacetylase assays were performed using a ﬂuorometric
SIRT1 Assay Kit (CS1040; Sigma). Brieﬂy, the reaction was carried out
at 37 °C for 30 min. Deacetylase activity was detected as a ﬂuorescent
emission at 450 nm,with an excitationwavelength of 360 nm. The ﬂuo-
rescence intensity of the compounds at 450nmwas subtracted from the
baseline values measured in the assay.
2.8. Immunocytochemistry
Cells were ﬁxed with 4% paraformaldehyde, permeabilized with
0.2% Triton X-100, and incubated with anti-RANK, anti-c-FOS, anti-c-
Jun, anti-NFκB and anti-NFATc for 4 h at room temperature, washed, in-
cubated with secondary antibodies for 1 h at room temperature, and
mounted using a Vectashield mounting medium (Vector Laboratories,
Inc., Burlingame, CA). Fluorescent images were obtained using a confo-
cal microscope (Olympus FV-1000).
2.9. Western blot
Proteins (30 μg) were resolved in 10% SDS-polyacrylamide electro-
phoresis gels and transferred to nitrocellulose membranes (Amersham
Biosciences, Inc., Piscataway, NJ), which were then blocked and
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chemiluminescent reagent in a Supersignal West Dura Extended Dura-
tion Substrate Kit (Pierce Chemical, Rockford, IL). Signals from bands
were quantiﬁed using UN-SCAN-IT gel 5.1 software (Silk Scientiﬁc,
Inc., Orem, Utah). Results are expressed as relative densities.2.10. Reverse transcription-PCR (polymerase chain reaction) analysis
Total RNAwas extracted from cells using TRIzol reagent (Invitrogen,
SanDiego, CA). The PCR primers used to amplify RANKwere 5′-AAA CCT
TGG ACC AAC TGC AC-3′ (sense) and 5′-ACC ATC TTC TCC TCC CGA GT-
3′ (antisense). Equal amounts of RT-PCR products were separated on 1%
agarose gels and then stained with ethidium bromide.2.11. Quantitative real-time reverse transcription
Total RNAwas extracted from cells using TRIzol reagent (Invitrogen,
San Diego, CA). RANK and SIRT1 gene expressions were determined by
real-timePCRusing a LightCycler 96 system (RocheMolecular Biochem-
icals, Mannheim, Germany) instrument and LightCycler DNA Master
SYBR Green I (Roche) using 1 ng of reverse-transcribed total RNA. PCR
was performed at 95 °C for 10 min followed by 50 ampliﬁcations of
95 °C 10 s, 50 °C 10 s, and 72 °C 10 s. The following oligonucleotide
primers speciﬁc for RANK, SIRT1, and actin were used: RANK, 5′-TTAA
GCCAG TGCTTCACGGG-3′ (sense) and 5′-ACGTAGACCACGATGATGTC
GC-3′ (antisense); SIRT1, 5′-ACTGCAGAAACTTTTAGCCTTTCAA-3′
(sense) and 5′-GGC AAT GTT CCAAAGAAGTCTGT-3′ (antisense); and
actin, 5′-AAGTGCTTCTAGGCGGACTGTT-3′ (sense) and 5′-TTTTCTGCGCFig. 1. Suppression of RANKL-induced RANK expression by cilostazol in Raw 264.7 cells. A. Time
for 0, 6, 12 and 24 h with RANKL (100 ng/ml) (Aa). Cells were pretreated with cilostazol (30 μ
dependent RANKL-induced RANK protein expression. C. Inhibition of RANKL-stimulated RAN
(10 and 30 μM) for 4 h and then incubatedRANKL (100 ng/ml) for 24 h.D and E. Inhibitory effect
with that of recombinant SIRT1 (rSIRT1, 200 nM) in the absence or the presence of sirtinol (20
with cilostazol (30 μM) or rSIRT1 (200 nM) for 4 h, cellswere incubated furtherwith RANKL (10
experiments. *P b 0.05, **P b 0.01, ***P b 0.001 vs. none; #P b 0.05, ##P b 0.01, ###P b 0.001 vs.AAGTTAGGTTTTG-3′ (antisense). Data were analyzed using LightCycler
96 Software (Roche Molecular Biochemicals).
2.12. Statistical analyses
Results are expressed as means ± SEMs. The signiﬁcances of results
were determined by one-way analysis of variance (ANOVA) followed by
Tukey's Multiple Comparison Test. Student's t-test was used to deter-
mine the signiﬁcances of treatment effects. P values of b0.05 were con-
sidered signiﬁcant.
3. Results
3.1. Inhibition of RANK expression by cilostazol
RANK/RANKL signaling plays a critical role in osteoclast differentia-
tion. We tested time (0–24 h)-dependent RANKL (100 ng/ml)-
induced RANK mRNA expression in Raw 264.7 cells. As shown in
Fig. 1Aa, the RANK mRNA expression increased in the presence of
RANKL (100 ng/ml) in a time-dependent manner. Whether cilostazol
suppresses the expression of RANK at the transcription level was exam-
ined. After pretreatment with and without cilostazol (30 μM) for 4 h,
Raw 264.7 cells were incubated with RANKL (100 ng/ml) for various
times (0–24 h). RANKL-induced increase in RANK mRNA expression
wasmarkedly suppressed (Fig. 1Aa and Ab). Accordingly, RANK protein
expression was time-dependently increased by RANKL (100 ng/ml)
(Fig. 1B). This RANKL-induced RANK expression (2.13 ± 0.08-fold, P b
0.001) was signiﬁcantly attenuated by pretreatment with cilostazol
(30 μM) for 4 h to 1.02 ± 0.08-fold (P b 0.001) (Fig. 1C).-dependent RANKL (100 ng/ml)-stimulated RANKmRNA expression. Cells were incubated
M) for 4 h and then incubated for indicated time with RANKL (100 ng/ml) (Ab). B. Time-
K protein expression by cilostazol (10 and 30 μM). Cells were pretreated with cilostazol
of cilostazol on RANKL-inducedRANKmRNA (D) and protein (E) expressions as compared
μM). Cells were incubated with or without sirtinol (20 μM) for 30min. After pretreatment
0 ng/ml) for 12 h (mRNA) or 24 h (protein). Results are expressed as themeans±SEMof 4
RANKL (100 ng/ml) alone; †P b 0.05, ††P b 0.01 vs. cilostazol or rSIRT1 alone.
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sions (at the mRNA and protein levels) is ascribed to the SIRT1 action
was examined under treatment with rSIRT1 (200 nM) compared with
cilostazol (30 μM) in the absence and presence of sirtinol (20 μM, a
SIRT1 inhibitor). Cilostazol inhibited RANKL-induced RANK mRNA and
protein expressions as did rSIRT1, and the inhibitory effects of both
agents were signiﬁcantly blocked by pretreatment with sirtinol
(Fig. 1D & E).
3.2. The up-regulation of SIRT1 expression and activity by cilostazol in Raw
264.7 cells
SIRT1 mRNA expression was signiﬁcantly elevated after treating
Raw 264.7 cells with cilostazol (30 μM) for 12–24 h (Fig. 2A). However,
SIRT1 protein levels were not increased after 12 h of treatment with
cilostazol (10–30 μM), but were signiﬁcantly increased at 24 h (Fig. 2B
& C). Furthermore, treatment with rSIRT1 (200 nM) resulted in marked
increases in SIRT1 expression (Fig. 2D).
Interestingly, SIRT1 activity rapidly increased after treatment with
cilostazol (30 μM) and plateaued at 1 to 24 h. This increase was
inhibited by pretreatment with sirtinol (20 μM) for 30 min, a SIRT1 in-
hibitor (Fig. 2E and F), indicating that cilostazol signiﬁcantly enhanced
the activity and expression of SIRT1.
In immunoﬂuorescence assessment, to verify the universality of this
drug we identiﬁed the effect of cilostazol on RANKL-induced RANK ex-
pression in BMMs from mice and the Raw 264.7 cell line (in vitro) and
in the CIA mouse model (in vivo). As shown in Fig. 3A and B, RANKL
(100 ng/ml) potently enhanced RANK protein expression in both
BMMs and Raw 264.7 cells. Interestingly, expression of RANKwasmark-
edly reduced in cells treated with either cilostazol (30 μM) or rSIRT1
(200 nM) in both cells. In addition, these reduced expressions were
blocked by sirtinol pretreatment (20 μM). Furthermore, RANK was
expressed at high levels in the joint (synovial) tissues of CIA mice
(Fig. 3C), and these expressions were markedly lower in the cilostazol-Fig. 2. The upregulation of SIRT1 expression and its activity by cilostazol in Raw 264.7 cells. A.
protein expression after cilostazol (10–30 μM) treatment for 12 h (B) and 24h (C). D. Conﬁrmat
increase in cilostazol-stimulated SIRT1 activity as determined by ELISA. F. Inhibition of cilostazo
for 30min and then incubated cilostazol (30 μM) for 1 h. Results are expressed as themeans±
(30 μM) alone.treated mice (30 mg/kg/day). Overall, these results conﬁrmatively indi-
cate that cilostazol inhibits the RANKL-induced up-regulation of RANK
at the mRNA and protein levels by activating SIRT1.
3.3. Suppression of RANKL-induced PU.1 activation by cilostazol
PU.1 plays a key role in osteoclast differentiation by regulating RANK
gene transcription in response to M-CSF and RANKL [13]. Therefore, we
assessed whether cilostazol inhibits RANKL-induced RANK expression
by inhibiting PU.1. RANKL (100 ng/ml) signiﬁcantly increased thenucle-
ar translocation of PU.1 in a time-dependent manner (Fig. 4A). Further,
the RANKL-induced nuclear translocation of PU.1 was concentration-
dependently suppressed by cilostazol (10–30 μM), and this inhibitory
effect of cilostazol was blocked by pretreatment with sirtinol (20 μM)
(Fig. 4B and C). Since RANKL-induced PU.1 nuclear translocation was
strongly suppressed by cilostazol and by rSIRT1, whether RANKL-
induced RANK expression is inﬂuenced by PU.1 gene silencing in Raw
264.7 cells was examined. PU.1 protein expression was reduced to
~22% by silencing the PU.1 gene, (Fig. 4D). When Raw 264.7 cells
were transfected with scrambled siRNA duplex (negative control),
RANKL-induced RANK was highly expressed to 1.93 ± 0.08-fold (P b
0.01), and this was signiﬁcantly inhibited by cilostazol (30 μM) to
0.99 ± 0.27-fold (P b 0.01), which was blocked by sirtinol (20 μM).
However, RANKL failed to stimulate RANK expression when the PU.1
gene was silenced (Fig. 4E), indicating that PU.1 plays an indispensable
role as a transcription factor in the expression of RANK.
3.4. Inhibition of transcriptional factors
It is known that RANK activation by osteoblast-expressed RANKL
commits these cells to the osteoclast fate, and that this process is me-
diated by various transcription factors, such as, NF-κB and c-Fos [5].
In the present study, immunoﬂuorescence results showed that
RANKL (100 ng/ml) + M-CSF (30 ng/ml) upregulated transcriptionTime-dependent increase in SIRT1 mRNA expression by cilostazol (30 μM). B and C, SIRT1
ion of the up-regulation of SIRT1 by rSIRT1 (200 nM) in Raw264.7 cells. E. Time-dependent
l-stimulated SIRT1 activity by sirtinol (20 μM). Cells were pretreatedwith sirtinol (20 μM)
SEM of 4 experiments. *P b 0.05, **P b 0.01, ***P b 0.001 vs. none; ###P b 0.001 vs. cilostazol
Fig. 3. Immunoﬂuorescence confocal microscopic images showing the inhibitory effects of cilostazol and of rSIRT1 (200 nM) on RANKL (100 ng/ml)-induced increases in RANK expression
(red color) in BMMs (A) and Raw 264.7 cells (B). Cells were pretreated with cilostazol (30 μM) or rSIRT1 (200 nM) for 4 h and then incubated RANKL (100 ng/ml) for 24 h. C. Increased
expression of RANK (red) in the knee joint (synovial) tissue of a CIAmouse (original magniﬁcation, ×200) treatedwith vehicle and cilostazol (30mg/kg/day for 6 days, intraperitoneally)
as compared with the synovial tissue of a control DBA1/J mouse. The photographs shown are a representative of four experiments that produced similar results. The blue color represents
DAPI nuclear staining.
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mice, and that these up-regulations were strongly suppressed by
cilostazol (30 μM) (Fig. 5).
3.5. Inhibition of osteoclastogenesis by cilostazol
To determine whether cilostazol inhibits osteoclast differentiation,
BMMs that were cultured with M-CSF plus RANKL were then incubatedFig. 4. A. Time-dependent (0–60 min) increases in nuclear PU.1 levels by RANKL (100 ng/ml). B
RANKL (100 ng/ml) in Raw 264.7 cells. Cells were pretreated with cilostazol (30 μM) for 4 h an
PU.1 expression by sirtinol (20 μM). Cells were incubated with or without sirtinol (20 μM) fo
RANKL (100 ng/ml) for further 30 min. D. Analyses of PU.1 knockdown effect versus negative c
siRNA oligonucleotide (100 nM). E. Loss of the effect of RANKL (100 ng/ml) on RANK expressio
controls. Cells were incubated with or without sirtinol (20 μM) for 30 min. After pretreatment
24 h. Results are expressed as themeans± SEM of 4–5 experiments. **P b 0.01, ***P b 0.001 vs. n
(30 μM).with cilostazol. M-CSF (30 ng/ml) plus RANKL (100 ng/ml) increased
the differentiation of BMMs into multinucleated (more than three nuclei
per cell) TRAP+-giant cells after 14 days of incubation, and this differenti-
ation was markedly inhibited by cotreatment with cilostazol (30 μM)
(Fig. 6A). Extensive resorption pit formation observed after 28 days of in-
cubation in the presence of RANKL (100 ng/ml) andM-CSF (30 ng/ml) on
dentin slices was also inhibited as evidenced by the decreased resorption
pits by cotreatment with cilostazol (30 μM) (Fig. 6B).. Cilostazol (10–30 μM)-induced decrease in nuclear PU.1 expression that was elevated by
d then incubated RANKL (100 ng/ml) for 30 min. C. Blockade of cilostazol-induced nuclear
r 30 min. After pretreatment with cilostazol (30 μM) for 4 h, cells were incubated with
ontrols in Raw 264.7 cells, showing reduced PU.1 expression in cells transfected with PU.1
n in PU.1 gene silenced Raw 264.7 cells as compared with the effect of RANKL on negative
with cilostazol (30 μM) for 4 h, cells were incubated with RANKL (100 ng/ml) for further
one; #P b 0.05, ##P b 0.01, ###P b 0.001 vs. RANKL (100 ng/ml) alone; †P b 0.05 vs. cilostazol
Fig. 5. Suppression by cilostazol of the M-CSF/RANKL-stimulated expressions of the osteoclast-related transcription factors c-FOS, c-Jun, NF-κB, and NFATc1, which are known to act as
positive modulators of osteoclast differentiation. BMMs from mice were incubated with or without sirtinol (20 μM) for 30 min. After pretreatment with cilostazol (30 μM) for 4 h, cells
were incubated with RANKL (100 ng/ml) for 1 h. The photographs shown are a representative of three experiments that produced similar results.
2142 S.Y. Park et al. / Biochimica et Biophysica Acta 1852 (2015) 2137–2144Osteoclasts aremultinucleated cells formed by the fusion of hemato-
poietic lineage-derived monocytes–macrophages and phenotypically
characterized by high TRAP levels (TRAP is an earlymarker of osteoclas-
tic lineage commitment). Thus, we assessed the effect of cilostazol on
TRAP activity after adding RANKL to BMMs and Raw 264.7 cells. Incuba-
tion with cilostazol (30 μM) signiﬁcantly reduced RANKL (100 ng/ml)
plus M-CSF (30 ng/ml)-induced increases in TRAP (an osteoclast mark-
er) activity from 0.379 ± 0.08 to 0.115 ± 0.03 (ΔOD 405 nM; P b 0.01)
(Fig. 6C).
To investigate themechanism bywhich cilostazol inhibits osteoclast
differentiation, we focused on the role of SIRT1. As shown in Fig. 6D,
RANKL plus M-CSF-induced increased TRAP activity in mouse BMM
cells was signiﬁcantly attenuated by pretreatment with cilostazol
(30 μM), as waswith rSIRT1 (200 nM) (both drugs treated for 4 h). Pre-
treatment with sirtinol blocked this cilostazol-induced inhibition of
TRAP activity as it antagonized rSIRT1-induced inhibition. These ﬁnd-
ings were similarly identiﬁed in the Raw 264.7 cells (Fig. 6D and E).
These results indicate that cilostazol strongly inhibits RANKL-induced
osteoclastogenesis by decreasing TRAP activity and resorbing the activ-
ity of osteoclast formation.
4. Discussion
The present study demonstrates that cilostazol suppresses RANKL-
stimulated RANK expression by inhibiting the nuclear translocation of
PU.1 by upregulating SIRT1, and that this attenuates osteoclast forma-
tion. Many reports have revealed that the pathogenic mechanisms of
bone destruction in a CIA mouse model are largely dependent on
RANKL generation in osteoclast formation [20,21].RANK plays important roles during osteoclastogenesis, as RANKL spe-
ciﬁcally binds to RANK on osteoclast precursors, and this prompts osteo-
clast differentiation in the presence of M-CSF [9,10]. Therefore, it is
plausible that control of the RANKL/RANK signaling pathway provides a
target for the suppression of osteoclast differentiation/activation. In the
present study, RANK protein levels signiﬁcantly increased in a time-
dependent (12–48 h) manner after RANKL stimulation, and RANKL-
induced RANK expressionwasmarkedly attenuated by cilostazol. Our re-
sults indicate that cilostazol-induced inhibition of RANK mRNA and pro-
tein expressionwas mediated via SIRT1 activation. OurWestern blot and
immunoﬂuorescence studies in Raw 264.7 cells showed that RANKL-
induced RANK expression was signiﬁcantly attenuated by cilostazol and
by rSIRT1, and that the effects of cilostazol and rSIRT1 were signiﬁcantly
blocked by sirtinol (an inhibitor of SIRT1). These ﬁndings were re-
examined in CIA mice, in which RANK was highly expressed. However,
elevated RANK expression in these mice was markedly reduced by
cilostazol. Accordingly, our results indicate that cilostazol inhibits
RANKL-induced osteoclastogenesis by activating SIRT1, and thus, reduc-
ing RANK expression.
During osteoclastogenesis, RANKL induces and activates various
transcription factors, such as, NF-κB, c-Fos, and NFAT (nuclear factor of
activated T-cells)c1, which act as positive modulators of osteoclast dif-
ferentiation [5]; binding of c-Fos to theNFATc1promoter region induces
NFATc1 gene expression [22,23]. In addition, we found that RANKL in-
duced upregulations of c-Fos, c-Jun, NF-κB, and NFATc1 in BMMs, and
these up-regulations were strongly suppressed by cilostazol, indicating
that RANKL-induced transcription factors were down-regulated by
cilostazol. However, the molecular mechanism(s) by which cilostazol
inhibits transcription factors have not been determined.
Fig. 6. Inhibition of M-CSF/RANKL-induced osteoclast differentiation by cilostazol via up-regulation of SIRT1 in osteoclast precursor cells. A. M-CSF (30 ng/ml) plus RANKL (100 ng/ml) en-
hanced the differentiation of BMMs into multinucleated TRAP+-giant cells and the inhibition of this enhancement by cilostazol (30 μM) (cells were incubated for 14 days). B. Extensive re-
sorption pit formation on dentin slices in the presence ofM-CSF plus RANKLwith or without cilostazol (30 μM) for 28 days. C. Inhibitory effect of cilostazol onM-CSF plus RANKL-stimulated
TRAP activity in BMMs frommice. Cellswere pretreatedwith cilostazol (30 μM) for 4 h and then incubated RANKL (100ng/ml) for 72 h.D and E. Inhibitory effects of cilostazol andof rSIRT1 in
BMMs, and the prevention of these inhibitions by sirtinol in BMMs (D) and Raw 264.7 cells (E). Cells were incubated with or without sirtinol (20 μM) for 30 min. After pretreatment with
cilostazol (30 μM) for 4 h, cells were incubatedwith RANKL (100 ng/ml) for 72 h. Results are expressed as themeans± SEM of 4 experiments. **P b 0.01, ***P b 0.001 vs. none; ##P b 0.01 vs.
RANKL alone; †P b 0.05, ††P b 0.01, †††P b 0.001 vs. cilostazol or rSIRT1.
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and RANKL, and transcription factors, such as, PU.1 and NF-κB that are in-
volved in hematopoietic cell differentiation also affect osteoclast differen-
tiation. Yang and Karsenty [12] emphasized that PU.1 is absolutely
required for macrophage differentiation. Furthermore, Park et al. [17]
found that cilostazol down-regulated LPS-stimulated PU.1-linked TLR4
expression andNF-κB signal pathways, and then suppressed inﬂammato-
ry cytokine production in synovial macrophages from RA patients and
markedly inhibited the severity of CIA in mice. In the present study, we
observed that cilostazol inhibited RANKL-induced RANK expression by
inhibiting PU.1, which is consistent with a previous report by Kwon
et al. [13]. In particular, RANKL signiﬁcantly increased the nuclear translo-
cation of PU.1, and this was concentration-dependently suppressed by
cilostazol (10–30 μM). In light of the above-mentioned reports andour re-
sults, it appears that PU.1 is importantly implicated in RANKL-induced
RANK expression and that this is strongly inhibited by cilostazol.
The question arises as to how cilostazol-stimulated SIRT1 inhibits
the nuclear translocation of PU.1 in Raw 264.7 cells. According to Bai
et al. [25], PU.1 activity was increased by p300 (a coactivator acetyl-
transferase protein), and this acetylation was necessary for maximal
PU.1 transactivation. Recently, Shakibaei et al. [19] reported that the ac-
tivation of SIRT-1 (a histone deacetylase) by resveratrol induced an as-
sociation between SIRT-1 and p300 in bone-derived and preosteoblastic
cells, and that this association led to the deacetylation of RANKL-induced NF-κB, which inhibited the transcriptional activation of NF-κB
and osteoclastogenesis. Interestingly, Lee et al. [26] reported increased
P300 expression induced by Aβ accumulation in N2aSwe cells (murine
neuroblastoma cells) was signiﬁcantly inhibited by cilostazol and res-
veratrol. These results suggest that reduced nuclear translocation of
PU.1 by cilostazol is due to the increased deacetylation of PU.1 caused
by SIRT1 activation. Further study is required to deﬁne the signal path-
way by which cilostazol inhibits the nuclear translocation of PU.1.
Osteoclasts aremultinucleated cells formed by the fusion of hemato-
poietic lineage-derived monocytes–macrophages, and should satisfy
the major criteria of osteoclasts, which include a high level of TRAP
[27]. Therefore, we assessed the effect of cilostazol on TRAP activity
after RANKL application in BMMs and Raw 264.7 cells previously ex-
posed toM-CSF. Aswas expected, incubationwith cilostazol signiﬁcant-
ly reduced RANKL-induced increases in TRAP activity. Intriguingly,
cilostazol suppressed synovial cell proliferation by arresting the G2/M
phases of the cell cycle, and cilostazol increased HO-1 messenger RNA
and protein expression. Increased expression of TNFα, interleukin-1β,
and IL-6 induced by lipopolysaccharide was attenuated by cilostazol in
conjunction with HO-1 [16].
Taken together, we conclude that cilostazol inhibits osteoclast differ-
entiation during arthritic reaction by inhibiting the PU.1-linked RANK
expression via SIRT1 activation, and consequently cilostazol inhibits
RANKL-induced osteoclastogenesis.
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